Japan To Become First Market For Troubled Brodalumab
Executive Summary
The interleukin-targeting antibody brodalumab will have its first launch worldwide this week, in Japan for various forms of psoriasis.
You may also be interested in...
LEO Pharma Gets EU Go-Ahead For Psoriasis Latecomer Brodalumab
The Danish speciality dermatology company LEO Pharma has achieved a key plank in its plans to provide products for the range of psoriasis patients with an EU go-ahead for brodalumab.
Suicide Warnings For Valeant’s Siliq Could Hinder Access To Psoriasis Treatment
While an FDA advisory committee unanimously supported approval of the plaque psoriasis drug brodalumab, several recommended a black box warning on suicide risk that could limit sales of the drug.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.